Eva-Maria Hempe, NVIDIA, says AI collaboration optimizes life science research via routine automation, freeing human experts for complex strategy, ethics, and exploring scarce data.

Eva-Maria Hempe, NVIDIA, says AI platforms must integrate R&D data, overcoming silos, with adoption demanding a centralized strategy and change management.

CPHI 2025 awards spotlight progress in pharmaceutical manufacturing, API development, automated processing, and sustainability driving future production.

As Thermo Fisher’s Jennifer Cannon explains in this first part of a two-part interview, the collaboration is intended to help improve the speed and success of drug development.

Pharmaceutical Technology® spoke with Peter Freed, head of Global Pharma CTS, Roquette, about a variety of materials-related topics including protein stability, tablet coating, sustainability, and securing the supply chain.

Maggie Saykali, Cefic, emphasizes the importance of competitiveness and innovation for European manufacturers to create added value and maintain environmental standards.

Nigel Langley of gChem discusses the company’s DMSO, proactive pharma strategies, and more in part 1 of a 2-part interview related to his presentation at CPHI Europe 2025.

ACG showcased the expansion of its European presence, and Bora Pharmaceuticals participates in a discussion about CDMO innovation.

Eva-Maria Hempe, NVIDIA, says bio/pharma must centralize AI strategy, tackle silos, prioritize process integrity, and balance quick wins with long-term drug design goals.

Maggie Saykali, Cefic, reviews how the EU’s proposed Critical Medicines Act aims to curb supply dependence and shortages by reforming drug procurement.

Eva-Maria Hempe, NVIDIA, explains that accelerated computing, data governance, and “lab in the loop” are key to bio/pharma’s AI strategy for transforming drug discovery and R&D.

Pharmaceutical Technology® spoke with Dr. Weite Oldenziel, CEO of Ofichem, before CPHI Frankfurt 2025 to get his perspective on the API market and why it is important to qualify API suppliers.

Patient adherence is improving thanks to technologies that offer a more personalized experience, deepening the connection between consumers and healthcare brands.

Pharmaceutical Technology® spoke with Christian Dowdeswell, managing director, Arcinova, a Quotient Sciences Company, ahead of CPHI Frankfurt 2025 to find out what makes an end-to-end service provider beneficial to sponsor companies and how digital technologies are changing the industry.

Radiopharmaceuticals are allowing for the targeted treatment of cancers, but they do pose challenges.

Vishal Mukund Sonje, Vaccine Manufacturing Lead, CEPI, talks about the challenges that arise in the manufacturing of vaccines in various global regions and gives a preview of his presentation at CPHI Frankfurt 2025.

In this interview, SGD’s Najet Mebarki previews more than a half dozen products and services the company will showcase at the conference.

Pharmaceutical packaging plays an important role in sustainability efforts. Maija Pohjakallio, VP, Climate and Circular Economy, Metsä Group, explains how fiber-based packaging can help with these efforts.

Pharmaceutical Technology® spoke with Tara Dougal, Event Director for Pharma at Informa Markets about what attendees at CPHI Frankfurt should expect this year.

Pharmaceutical Technology® spoke with Tara Dougal, Event Director for Pharma at Informa Markets about what attendees at CPHI Frankfurt should expect this year.

US domestic manufacturing investment, R&D model shifts, new excipients, and digital traceability are redefining drug development and supply chains.

SK pharmteco boosts US peptide synthesis and purification capabilities, advancing reliable large-scale manufacturing for biopharma innovation.

The new partnership will work to embed digital identification into labware, solving chain-of-identity challenges for individualized cell and gene therapies.

Real-world data can be utilized to ensure quality and effectiveness of drug products.

In this episode of the Ask the Expert video series, Susan J. Schniepp, Regulatory Compliance Associates, and Siegfried Schmitt, Parexel, give their opinions on why those working in the pharmaceutical industry should lend their voices to draft regulations.

Non-parenteral alternatives for biologics remain a clinical imperative and a formidable challenge.

Recent developments show how innovations and treatments for cancer are rapidly advancing.

Major pharmaceutical investments in the United States are expanding API, capsule, and packaging capacity, enhancing supply chain resilience and supporting domestic drug production.